Patient P-01517
Therapy response
Unstable
Tolerance
Stable
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
84%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S06
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 GI symptom burden −10% vs expected — Dietary Support Protocol NP-02
- Day 48 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 48 Tolerance state changed — Unstable → Improving
- Day 57 GI-04 recommended — GI Support Protocol GI-04
- Day 58 Patient declined — Not now
What changed?
Trajectory began diverging from predicted response on Day 48.
Primary contributors, last 14 days
- GI instability-4
- Nutritional resilience+4
- Treatment adherence+3
- Inflammatory activity+2
- Toxicity+2
What helped?
- Dietary Support Protocol NP-02Day 31Result: symptom burden −10%
- GI Support Protocol GI-04Day 57Declined by patient
LIFE OS recommendation
GI Support Protocol GI-04
85%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 84% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 62 and rising
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 43/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↑70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 65
- Autonomic recovery ↑45
- WearableResting HR 81 bpm
- Wearable3,244 steps/day
- Drug metabolism and exposure ↑20
- BloodToxicity index 52
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Intermediate metabolizerExpected exposure
Microbiome
Shannon diversity 2.3 · butyrate capacity 43/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 37 ms
- Sleep
- 7.2 h
- Steps
- 3,679
- Resting HR
- 79 bpm
Daily log: GI score 62, nutritional resilience 37, adherence 45.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01655 | 48% | S14 | GI-04 | no change | 29 |
| P-01564 | 45% | S14 | ME-01 | improved | 39 |
| P-01605 | 44% | S14 | ME-01 | improved | 41 |
| P-01765 | 44% | S14 | SC-12 | improved | 31 |
| P-01619 | 43% | S14 | GI-04 | worsened | 38 |
| P-01728 | 43% | S14 | SC-12 | improved | 41 |
| P-01813 | 43% | S01 | NP-02 | no change | 40 |
| P-01887 | 43% | S12 | ME-01 | improved | 43 |
| P-01675 | 42% | S14 | NP-02 | improved | 38 |
| P-01721 | 42% | S14 | — | — | 37 |
| P-01737 | 42% | S14 | — | — | 28 |
| P-01811 | 42% | S13 | — | — | 41 |